Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863 is registered in ClinicalTrials.gov with Clasp Therapeutics, Inc. as lead sponsor.

NCT NCT06778863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06778863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Lead sponsor
Clasp Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 28, 2025
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, breast cancer, colorectal adenocarcinoma, head and neck squamous cell carcinoma, lung cancer, metastatic solid tumor, ovarian cancer, pancreatic adenocarcinoma, prostate cancer, unresectable solid tumor